Theranexus Société Anonyme (ALTHX.PA)
EUR 0.64
(32.37%)
EUR 0.64
(32.37%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 296.33 Thousand EUR | -28.58% |
| 2022 | 414.89 Thousand EUR | 68819.93% |
| 2021 | 602.00 EUR | -99.8% |
| 2020 | 294.6 Thousand EUR | -47.75% |
| 2019 | 563.85 Thousand EUR | 408.3% |
| 2018 | 110.92 Thousand EUR | -24.96% |
| 2017 | 147.83 Thousand EUR | 63.23% |
| 2016 | 90.56 Thousand EUR | -83.87% |
| 2015 | 561.35 Thousand EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 2.21 Million EUR | 0.0% |
| 2023 Q4 | 74.66 Thousand EUR | 0.0% |
| 2023 FY | 296.33 Thousand EUR | -28.58% |
| 2023 Q2 | 244.33 Thousand EUR | 0.0% |
| 2022 Q4 | 2245.00 EUR | 0.0% |
| 2022 FY | 414.89 Thousand EUR | 68819.93% |
| 2022 Q2 | 412.65 Thousand EUR | 0.0% |
| 2021 Q2 | 1822.00 EUR | 0.0% |
| 2021 FY | 602.00 EUR | -99.8% |
| 2021 Q4 | -1220.00 EUR | 0.0% |
| 2020 Q4 | 15.7 Thousand EUR | 0.0% |
| 2020 FY | 294.6 Thousand EUR | -47.75% |
| 2020 Q2 | 278.9 Thousand EUR | 0.0% |
| 2019 FY | 563.85 Thousand EUR | 408.3% |
| 2019 Q4 | 9935.00 EUR | 0.0% |
| 2019 Q2 | 553.91 Thousand EUR | 0.0% |
| 2018 FY | 110.92 Thousand EUR | -24.96% |
| 2018 Q4 | 47.71 Thousand EUR | 0.0% |
| 2018 Q2 | 63.21 Thousand EUR | 0.0% |
| 2017 FY | 147.83 Thousand EUR | 63.23% |
| 2017 Q4 | 97.21 Thousand EUR | 0.0% |
| 2017 Q1 | 36.95 Thousand EUR | -26.51% |
| 2017 Q2 | 50.62 Thousand EUR | 36.97% |
| 2016 Q2 | 40.27 Thousand EUR | 0.0% |
| 2016 FY | 90.56 Thousand EUR | -83.87% |
| 2016 Q1 | - EUR | 0.0% |
| 2016 Q4 | 50.29 Thousand EUR | 0.0% |
| 2015 Q2 | - EUR | 0.0% |
| 2015 Q3 | - EUR | 0.0% |
| 2015 Q4 | - EUR | 0.0% |
| 2015 FY | 561.35 Thousand EUR | 0.0% |
| 2015 Q1 | - EUR | 0.0% |
| 2014 Q4 | - EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | 93.614% |
| ABIVAX Société Anonyme | 4.62 Million EUR | 93.587% |
| Adocia SA | 2.15 Million EUR | 86.217% |
| Aelis Farma SA | 9.05 Million EUR | 96.727% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | 90.596% |
| genOway Société anonyme | 20.04 Million EUR | 98.522% |
| IntegraGen SA | 12.53 Million EUR | 97.636% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | 1.234% |
| Neovacs S.A. | 533.41 Thousand EUR | 44.446% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | 82.377% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -1396.924% |
| Sensorion SA | 4.74 Million EUR | 93.752% |
| TME Pharma N.V. | 17 Thousand EUR | -1643.124% |
| Valbiotis SA | 4.73 Million EUR | 93.739% |
| TheraVet SA | 1.07 Million EUR | 72.512% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | 83.537% |
| argenx SE | 1.13 Billion EUR | 99.974% |
| BioSenic S.A. | 543 Thousand EUR | 45.427% |
| Celyad Oncology SA | 102 Thousand EUR | -190.521% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Galapagos NV | 239.72 Million EUR | 99.876% |
| Genfit S.A. | 28.56 Million EUR | 98.963% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | 85.801% |
| Innate Pharma S.A. | 51.9 Million EUR | 99.429% |
| Inventiva S.A. | 17.47 Million EUR | 98.304% |
| MaaT Pharma SA | 2.22 Million EUR | 86.7% |
| MedinCell S.A. | 9.16 Million EUR | 96.765% |
| Nanobiotix S.A. | 30.05 Million EUR | 99.014% |
| Onward Medical N.V. | 532 Thousand EUR | 44.299% |
| Oryzon Genomics S.A. | 14.19 Million EUR | 97.912% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 86.694% |
| Oxurion NV | 263 Thousand EUR | -12.673% |
| Pharming Group N.V. | 245.31 Million EUR | 99.879% |
| Poxel S.A. | 1.98 Million EUR | 85.041% |
| GenSight Biologics S.A. | 1.26 Million EUR | 76.612% |
| Transgene SA | 1.18 Million EUR | 74.972% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 99.994% |
| Valneva SE | 153.71 Million EUR | 99.807% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 108.186% |